{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:25:46Z","timestamp":1791314746269,"version":"4.3.1"},"reference-count":82,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["aiche.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biotechnology Progress"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Monoclonal antibodies (mAbs) are effective therapeutic agents against many acute infectious diseases including COVID\u201019, Ebola, RSV,\n                    <jats:italic>Clostridium difficile<\/jats:italic>\n                    , and Anthrax. mAbs can therefore help combat a future pandemic. Unfortunately, mAb development typically takes years, limiting its potential to save lives during a pandemic. Therefore \u201cpandemic mAb\u201d timelines need to be shortened. One acceleration tool is \u201cdeferred cloning\u201d and leverages new Chinese hamster ovary (CHO) technology based on targeted gene integration (TI). CHO pools, instead of CHO clones, can be used for Phase I\/II clinical material production. A final CHO clone (producing the mAb with a similar product quality profile and preferably with a higher titer) can then be used for Phase III trials and commercial manufacturing. This substitution reduces timelines by ~3\u2009months. We evaluated our novel CHO TI platform to enable deferred cloning. We created four unique CHO pools expressing three unique mAbs (mAb1, mAb2, and mAb3), and a bispecific mAb (BsAb1). We then performed single\u2010cell cloning for mAb1 and mAb2, identifying three high\u2010expressing clones from each pool. CHO pools and clones were inoculated side\u2010by\u2010side in ambr15 bioreactors. CHO pools yielded mAb titers as high as 10.4\u2009g\/L (mAb3) and 7.1\u2009g\/L (BsAb1). Subcloning yielded CHO clones expressing higher titers relative to the CHO pools while yielding similar product quality profiles. Finally, we showed that CHO TI pools were stable by performing a 3\u2010month cell aging study. In summary, our CHO TI platform can increase the speed to clinic for a future \u201cpandemic mAb.\u201d\n                  <\/jats:p>","DOI":"10.1002\/btpr.3399","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T15:14:16Z","timestamp":1698160456000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Utilizing targeted integration\n                    <scp>CHO<\/scp>\n                    pools to potentially accelerate the\n                    <scp>GMP<\/scp>\n                    manufacturing of monoclonal and bispecific antibodies"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9869-0307","authenticated-orcid":false,"given":"Gavin C.","family":"Barnard","sequence":"first","affiliation":[{"name":"Cell Culture and Bioprocess Operations Genentech  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Zhou","sequence":"additional","affiliation":[{"name":"Cell Culture and Bioprocess Operations Genentech  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3401-4569","authenticated-orcid":false,"given":"Amy","family":"Shen","sequence":"additional","affiliation":[{"name":"Cell Culture and Bioprocess Operations Genentech  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inn H.","family":"Yuk","sequence":"additional","affiliation":[{"name":"Cell Culture and Bioprocess Operations Genentech  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Laird","sequence":"additional","affiliation":[{"name":"Cell Culture and Bioprocess Operations Genentech  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"University of Oxford.Our World in Data: Daily Confirmed COVID\u201019 Deaths by World Region. Accessed June 6 2023https:\/\/ourworldindata.org\/grapher\/daily-covid-deaths-region"},{"key":"e_1_2_9_3_1","unstructured":"World Health Organization.WHO Coronavirus (COVID\u201019) Dashboard. Accessed June 6 2023https:\/\/covid19.who.int"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3207"},{"key":"e_1_2_9_5_1","unstructured":"Centers for Medicare and Medicaid Services.COVID\u201019 Monoclonal Antibodies. Accessed June 6 2023https:\/\/www.cms.gov\/monoclonal#:~:text=Bamlanivimab%20(EUA%20issued%20November%209 revoked%20April%2016%2C%202021"},{"key":"e_1_2_9_6_1","unstructured":"U.S. Food and Drug Administration.FDA News Release. FDA Takes Key Action in Fight Against COVID\u201019 By Issuing Emergency Use Authorization for First COVID\u201019 Vaccine. Accessed June 29 2023https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19"},{"key":"e_1_2_9_7_1","unstructured":"U.S. Food and Drug Administration.FDA News Release. FDA Takes Additional Action in Fight Against COVID\u201019 By Issuing Emergency Use Authorization for Second COVID\u201019 Vaccine. Accessed June 29 2023https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1286"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.2599"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.2495"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.2572"},{"key":"e_1_2_9_12_1","first-page":"1","article-title":"Shortening the biologics clinical timeline with a novel method for generating stable, high producing cell pools and clones","author":"Hall CA","year":"2023","journal-title":"Biotechnol Bioeng"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201700748"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.2447"},{"key":"e_1_2_9_15_1","unstructured":"ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological\/biological products \u2013 Scientific guideline. European Medicines Agency.1998Accessed June 23 2023https:\/\/www.ema.europa.eu\/en\/ich-q5d-derivation-characterisation-cell-substrates-used-production-biotechnological-biological"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/pr5020020"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coche.2018.09.010"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/biot.202000350"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.7182\/prtr.1.6.3.8145l3u185493182"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0803-865"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3040"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4305"},{"key":"e_1_2_9_23_1","first-page":"1","article-title":"Biopharmaceutical benchmarks 2022","volume":"5","author":"Walsh G","year":"2022","journal-title":"Nat Biotechnol"},{"key":"e_1_2_9_24_1","first-page":"40","article-title":"Recombinant protein therapeutics from CHO cells\u201020\u2009years and counting","volume":"103","author":"Jayapal KP","year":"2007","journal-title":"Chem Eng Prog"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23720-9"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-08-100623-8.00007-4"},{"key":"e_1_2_9_27_1","first-page":"11","volume-title":"Mammalian Cell Cultures for Biologics Manufacturing. Advances in Biochemical Engineering\/Biotechnology","author":"Estes S","year":"2014"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph6050579"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1026"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2008.12.003"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2021.02.003"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2016.01.001"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/biot.202100165"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2019.09.006"},{"key":"e_1_2_9_35_1","volume-title":"Tilting at Clones: A Regulatory Perspective on the Importance of \u201cClonality\u201d of Mammalian Cell Banks","author":"Welch J","year":"2017"},{"key":"e_1_2_9_36_1","volume-title":"Regulatory Considerations in Establishing Clonality for Cell Lines Expressing Therapeutic Proteins","author":"Jia A","year":"2016"},{"key":"e_1_2_9_37_1","unstructured":"RawatR.Regulatory consideration for biotechnology products: clonality of the production cell bank. In:Informa Life Sciences Annual Cell Line Development and Engineering Conference. Europe Vienna Austria.2016. Accessed June 29 2023https:\/\/www.moleculardevices.com\/sites\/default\/files\/en\/assets\/presentations\/bpd\/regulatory-consideration-for-biotechnology-products-clonality-of-production-cell-bank.pdf"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.2583"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.2467"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.2477"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.2493"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.2548"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0512-5"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2022.102798"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3186"},{"key":"e_1_2_9_46_1","first-page":"1","article-title":"Rapidly accelerated development of neutralizing COVID\u201019 antibodies by reducing cell line and CMC development timelines","author":"Tan KW","year":"2022","journal-title":"Biotechnol Bioeng"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.27995"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2022.03.010"},{"key":"e_1_2_9_49_1","volume-title":"Cell Culture Engineering XVIII","author":"Chen G","year":"2023"},{"key":"e_1_2_9_50_1","unstructured":"ShenY BurakovD ChenG FandlJP.Inventors; Regeneron pharmaceuticals Inc assignee. CHO integration sites and uses thereof. US Patent 9 816 110.2017."},{"key":"e_1_2_9_51_1","unstructured":"ShenY BurakovD ChenG FandlJP.Inventors; Regeneron pharmaceuticals Inc assignee. CHO integration sites and uses thereof. US Patent 11 268 109.2022."},{"key":"e_1_2_9_52_1","unstructured":"BabbR BurakovD ChenG FandlJP ZhaoY.Inventors; Regeneron pharmaceuticals Inc assignee. Compositions and methods for making antibodies based on use of an expression\u2010enhancing loci. US Patent 11 512 144.2022."},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3140"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gni145"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.26.14602"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering9040173"},{"key":"e_1_2_9_57_1","volume-title":"Osher Lifelong Learning Institute","author":"University of Cincinnati","year":"2021"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-15346-5_2"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAJ.0000731640.35662.2c"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01829-6"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0673-1"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0113-8"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.621043"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010481"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008186113245"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0290(20000720)69:2<204::AID-BIT9>3.0.CO;2-Z"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0290(19980405)58:1<73::AID-BIT8>3.0.CO;2-R"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.24367"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.23189"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.24485"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.26231"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.26823"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.27715"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.10517"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2019.01.011"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coche.2018.09.011"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.27599"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1021\/acssynbio.8b00140"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1021\/acssynbio.8b00453"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2405"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0202"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32551-2"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.27774"}],"container-title":["Biotechnology Progress"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aiche.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/btpr.3399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:41:12Z","timestamp":1760046072000},"score":1,"resource":{"primary":{"URL":"https:\/\/aiche.onlinelibrary.wiley.com\/doi\/10.1002\/btpr.3399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/btpr.3399"],"URL":"https:\/\/doi.org\/10.1002\/btpr.3399","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/BTPR.3399\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BTPR.3399\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BTPR.3399\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BTPR.3399\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BTPR.3399\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BTPR.3399\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BTPR.3399\/v1\/decision1","asserted-by":"object"}]},"ISSN":["8756-7938","1520-6033"],"issn-type":[{"value":"8756-7938","type":"print"},{"value":"1520-6033","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"assertion":[{"value":"2023-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e3399"}}